To support this hypothesis, we investigated the effects of the hypoxia-mimicking compound IOX2, alongside TGFβ1 in terms of their synergistic capacity to recapitulate in vivo mechanisms in MASH patients. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatohepatitis.